The results from two Phase IIb paediatric studies investigating the safety, efficacy, and...
- ECCMID 2018: Avycaz set for paediatric label expansion following Phase IIb trials
- Completion of THX-110 trial marks a step forward for medical cannabis development
- AACR 2018: SLFN11 predicts response to PARP inhibition in small cell lung cancer
- TaiwanJ’s JKB-121 falls victim to unexpected placebo response in NASH patients
- ILC 2018: NGM’s intravenous NASH therapy shows rapid reduction in liver fat content and fibrosis
ECCMID 2018: Avycaz set for paediatric label expansion following Phase IIb trials
The results from two Phase IIb paediatric studies investigating the safety, efficacy, and pharmacokinetics of Avycaz for the treatment of complicated intra-abdominal infections and complicated urinary tract infections were presented at the 2018 European Congress of Clinical Microbiology and Infectious Diseases.
Completion of THX-110 trial marks a step forward for medical cannabis development
Therapix Biosciences, a biopharmaceutical company focused on the development of cannabinoid-based treatments, reported topline data on April 9th from a Phase IIa study at Yale University showing that its cannabinoid-based treatment, THX-110, met its primary endpoint for Tourette syndrome (TS). THX-110, which is a combination drug of dronabinol (THC) and palmitoylethanolamide (PEA), significantly improved symptoms in adult subjects with the disorder.
NovaDigm initiates Phase IIa trial of NDV-3A for S. aureus
NovaDigm Therapeutics has initiated a Phase IIa trial analysing NDV-3A for the treatment of Staphylococcus aureus (S. aureus) colonisation in a high-risk population of military trainees.
Catalyst Pharmaceuticals enrols first patient in MSK-002 trial
Catalyst Pharmaceuticals has enrolled the first patient in its MSK-002 trial, a Phase III clinical study evaluating the efficacy and safety of Firdapse (amifampridine phosphate) to treat patients with MuSK antibody positive Myasthenia Gravis (MuSK-MG).
Clementia Pharmaceuticals starts Phase II trial of palovarotene
Clementia Pharmaceuticals has commenced a Phase II trial evaluating the safety and efficacy of palovarotene for the treatment of paediatric patients with multiple osteochondromas (MO), also called multiple hereditary exostoses (MHE).
Gene therapy for beta-thalassaemia could eliminate need for transfusions
A gene therapy trial for transfusion-dependent thalassaemia, an inherited blood disorder, gave positive results in an interim analysis, with the majority of patients being transfusion-free following treatment.
Synlogic doses first subject in Phase I/IIa trial of SYNB1618
Synlogic has dosed the first subject in its Phase I/IIa clinical trial of SYNB1618, a Synthetic Biotic medicine being developed to treat phenylketonuria (PKU).
Summit Therapeutics ends dosing in PhaseOut DMD trial
Summit Therapeutics has completed patient dosing in the PhaseOut DMD clinical trial, a Phase II study of ezutromid to treat patients with duchenne muscular dystrophy (DMD), the most common and severe form of muscular dystrophy.
Qu Biologics to start Phase II trial of QBECO SSI to treat CD
Qu Biologics has received a ‘no objection letter’ (NOL) from Health Canada to commence a Phase II clinical trial of QBECO SSI for treatment of Crohn’s disease (CD).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.